Asia-Pacific myocardial infarction market is estimated to grow at the fastest CAGR of around 7.3% during the forecast period. Increasing cases related to CVD and heart attack, increasing healthcare infrastructure, and increasing unhealthy lifestyles among people in the region are some of the major factors for the growth of the market in Asia-Pacific. Moreover, increasing medical tourism and improving healthcare infrastructure are also contributing significantly to the growth of the myocardial infarction market in the region. The region provides future opportunities for growth as the demand for myocardial infarction treatment is continuously increasing in emerging economies such as India and China due to increasing cardiovascular disorders. According to the WHO, CVD causes one-third of the total fatalities each year in China. The rising geriatric population and associated prevalence of the chronic disease in them continue to spur the demand for myocardial infarction diagnosis and treatment.
The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.
The companies which are contributing to the growth of the Asia-Pacific myocardial infarction market include AstraZeneca PLC, Bayer AG, Abbott Laboratories Inc., GlaxoSmithKline PLC, Pfizer Inc., Koninklijke Philips N.V., Medtronic PLC, and Merck KGaA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Research Methodology
The market study of the Asia-Pacific myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Asia-Pacific Myocardial Infarction Market by Type
5.1.1. Non-ST-elevation myocardial infarction (NSTEMI)
5.1.2. ST-elevation myocardial infarction (STEMI)
5.1.3. Silent Heart Attacks
5.2. Asia-Pacific Myocardial Infarction Market by Device
5.2.1. Left Ventricular Assist Device (LVAD)
5.2.2. Pacemaker
5.2.3. Catheters
5.2.4. Implantable Cardioverter-Defibrillator (ICD)
5.2.5. Others (Stent Graft)
5.3. Asia-Pacific Myocardial Infarction Market by Diagnosis
5.3.1. Electrocardiography (ECG)
5.3.2. Chest X-Ray
5.3.3. Computed Tomography (CT Scan)
5.3.4. Echocardiography
5.3.5. Others (Blood Test)
5.4. Asia-Pacific Myocardial Infarction Market by Treatment
5.4.1. Medication
5.4.1.1. Analgesics
5.4.1.2. Thrombolytic
5.4.1.3. Antiplatelet Agents
5.4.1.4. Glycoprotein IIb/IIIa Inhibitors
5.4.1.5. Others (Beta-Adrenergic Blockers)
5.4.2. Surgery
5.4.2.1. Angioplasty
5.4.2.2. Bypass Surgery
5.4.2.3. Heart Transplant
5.5. Asia-Pacific Myocardial Infarction Market by End-User
5.5.1. Hospital & Clinics
5.5.2. Ambulatory Surgical Centers
5.5.3. Research Institutes
6. Regional Analysis
6.1. China
6.2. Japan
6.3. India
6.4. Rest of Asia-Pacific
7. Company Profiles
7.1. Abbott Laboratories Inc.
7.2. AstraZeneca PLC
7.3. Bayer AG
7.4. Boston Scientific Corp.
7.5. Bristol-Myers Squibb Co.
7.6. CSL Ltd.
7.7. Eli Lilly and Co.
7.8. GlaxoSmithKline Plc
7.9. Johnson & Johnson Services, Inc.
7.10. Medtronic PLC
7.11. Merck KGaA
7.12. Mesoblast Ltd.
7.13. Mylan N.V.
7.14. Novartis AG
7.15. Pfizer Inc.
7.16. Siemens AG
1. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
2. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DEVICE, 2019-2026 ($ MILLION)
3. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2019-2026 ($ MILLION)
4. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
5. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2019-2026 ($ MILLION)
6. ASIA-PACIFIC MYOCARDIAL INFARCTION TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
1. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
2. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET SHARE BY TYPE, 2019 VS 2026 (%)
3. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET SHARE BY DEVICE, 2019 VS 2026 (%)
4. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET SHARE BY DIAGNOSIS, 2019 VS 2026 (%)
5. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
6. ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET SHARE BY END-USERS, 2019 VS 2026 (%)
7. CHINA MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)
8. JAPAN MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)
9. INDIA MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)
10. REST OF ASIA-PACIFIC MYOCARDIAL INFARCTION MARKET SIZE, 2019-2026 ($ MILLION)